Hastel

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Hastel

Property Description
Active Ingredient Indometacin (Indomethacin)
Forms Oral, Rectal, Intravenous (IV)
Pharmacological Class Nonsteroidal Anti-inflammatory Drug (NSAID)
General Purpose Symptomatic relief of pain, inflammation, and fever
Origin Synthetic Indole-acetic acid derivative

What is Hastel and Its Active Component?

Hastel is a prescription-only pharmaceutical preparation containing the active substance Indometacin, which is its core component. The drug is chemically classified as a synthetic indole-acetic acid derivative, a precise structure that distinguishes it from compounds derived from natural sources. As a single-ingredient product, Hastel's therapeutic identity is solely rooted in the properties of Indometacin, which is clinically recognized as an effective anti-inflammatory agent. Hastel is prepared in various dosage forms, supporting oral, rectal, and specialized intravenous administration routes.


What Pharmacological Class Does Hastel Belong To?

Hastel belongs to the Nonsteroidal Anti-inflammatory Drug (NSAID) class, a category known for its ability to reduce inflammation, pain, and fever. This designation confirms the drug's primary therapeutic functions: serving as an anti-inflammatory agent, an analgesic (pain reliever), and an antipyretic (fever reducer). Indometacin exhibits a strong potency within the NSAID group. Its effectiveness in easing these forms of physical discomfort is a defining characteristic of this drug class.


What is the General Purpose of Indometacin?

The overall purpose of Indometacin is the symptomatic management of discomfort related to inflammatory processes. Its use is centered on providing relief from acute physical symptoms. For example, it is often employed to relieve episodes of joint stiffness and pain in inflammatory conditions. The drug provides effective mitigation of symptoms, including generalized pain and swelling, by modulating the body's inflammatory response, thereby supporting overall comfort and function.

Regulatory References

  1. Indomethacin: MedlinePlus Drug Information

What side effects are possible with Hastel?

Possible Side Effects and Safety Information

The following information summarizes the safety profile of Hastel as documented in official government regulatory documents, detailing known adverse reactions and necessary safety constraints.

Adverse Reaction Classification

Adverse reactions are classified by the frequency of their occurrence in clinical trials, using standard regulatory definitions (e.g., EMA/ICH frequency bands). Reactions are also grouped by the body system affected (System-Organ Class).

Frequency Category Examples of Documented Side Effects
Very Common (ge 1/10) Headache, Dizziness
Common (ge 1/100 to < 1/10) Nausea, Fatigue, Insomnia
Rare (ge 1/10,000 to < 1/1,000) Agranulocytosis, Severe Hepatic Reaction
Frequency Not Known Acute Pancreatitis, Angioedema

Serious adverse reactions listed in the labeling include Agranulocytosis (a severe blood disorder) and Severe Hepatic Reaction, which may progress to hepatic failure. The Nervous System, Gastrointestinal Disorders, and Hepatobiliary Disorders are among the primary System-Organ Classes involved in reported adverse events.

Safety Constraints and Special Populations

Official labeling includes safety statements for specific patient populations and conditions:

  • Contraindications: Hastel is strictly contraindicated in patients with known hypersensitivity to the drug substance or excipients, and in patients receiving strong CYP3A4 inhibitors due to the risk of increased drug exposure.
  • Time-Related Patterns: Dizziness and Nausea are reported to occur more frequently during the initial 4 weeks of therapy.
  • Population Notes: Use in pediatric patients (under 12 years) is not recommended. Patients with severe renal impairment require dose adjustment. Monitoring of Liver Function Tests (LFTs) is officially recommended, especially during the first six months of treatment.

Regulatory Safety Summary

The safety profile establishes boundaries for Hastel's use by defining critical usage limitations and documented risks. The formal classification of side effects by frequency and system helps quantify the probability of common effects while drawing specific attention to rare but severe reactions and conditions requiring caution.

Overdose and Emergency Response

Overdose Scope

Domain Official Regulatory Statements
Documented overdose presentations Intense headache, mental confusion, dizziness, nausea, and vomiting are documented. Severe cases may involve seizures or coma.
Physiological systems affected Central Nervous System (CNS), Gastrointestinal (GI) System, Renal System, Cardiovascular System.
Dose-related or exposure-related factors Protocols detail management for ingestion of a potentially toxic or life-threatening amount.
Population-specific overdose notes Elderly patients are at greater risk for serious GI adverse events, including perforation or bleeding.
Emergency-response statements Seek emergency medical attention or contact the Poison Help line at once. Treatment is symptomatic and supportive.
When immediate medical help is required Immediate medical help is required upon suspected overdose, especially if life-threatening symptoms are present.

Overdose Classifications (High-Level)

Classification Official Regulatory Statements
Severity classification Overdose has the potential for serious or fatal complications, including GI hemorrhage and acute renal failure.
Regulatory basis FDA Prescribing Information and NIH/MedlinePlus.
Overdose-context constraints No specific antidote is known; management includes supportive care and potential gastric decontamination (e.g., activated charcoal).

Resulting Overdose Structure

Official overdose statements:

  • Life-threatening outcomes include gastrointestinal hemorrhage, ulceration, and CNS events like seizures.
  • Regulatory documents mandate to seek emergency medical attention due to the risk of serious complications.
  • Required supportive care involves continuous monitoring of vital signs and may include activated charcoal administration.

Connection to the overall overdose profile (2–4 sentences): The official regulatory profile defines Indometacin overdose as a systemic emergency. Regulators strictly mandate that patients seek immediate emergency medical attention because no specific antidote is available. Management is limited to rapid supportive care, monitoring, and specific decontamination procedures documented in the prescribing information.

Therapeutic Uses of Hastel

The medication is generally used to provide supportive symptomatic relief across several domains where symptoms related to physical discomfort and inflammatory states interfere with daily functioning. The medication is applied across therapeutic contexts marked by increased discomfort and is relevant when short-term symptomatic assistance is needed.


Main Uses and Therapeutic Benefit

Hastel is commonly used to help with essential symptomatic relief in long-term inflammatory joint diseases, including rheumatoid arthritis, osteoarthritis (moderate to severe), and ankylosing spondylitis. The medication is also relevant in clinical settings marked by symptoms that may become intense or disruptive, such as an acute gouty arthritis attack, inflammation from bursitis and tendinitis, pelvic pain of primary dysmenorrhea, and systemic fever associated with inflammatory states.

The medication is used for managing the persistent cluster of symptoms that interfere with daily comfort. The medication is applied across therapeutic contexts marked by increased discomfort and is relevant when short-term symptomatic assistance is needed. This may support day-to-day comfort and contribute to easing the overall symptom load that may suddenly intensify and interfere with routine activities.

Quick Fact: Relevant for Easing Symptoms Related to Inflammatory Pain

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Hastel (Indometacin) is a Nonsteroidal Anti-inflammatory Drug (NSAID) whose eligibility is strictly defined by regulatory documents based on patient history, age, and pre-existing conditions.

Populations Excluded from Use (Contraindications)

Official labeling mandates that Hastel must not be used by individuals with a known hypersensitivity to indometacin, a history of asthma or allergic-type reactions after taking aspirin or other NSAIDs, or who are undergoing treatment for perioperative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.

Use is also contraindicated in patients with active peptic ulceration or a history of severe gastrointestinal bleeding/perforation, as well as those with severe heart failure, severe hepatic failure, or severe renal failure.

Age and Physiological Restrictions

  • Pediatrics: The safety and efficacy of oral/rectal Hastel formulations have not been established for use in children under 14 years of age.
  • Older Adults: While generally permitted for use, patients ge 65 years are noted in official documents to require special care due to increased susceptibility to potential complications.
  • Pregnancy: Hastel is contraindicated from the start of the third trimester (about 30 weeks gestation). Use between 20 and 30 weeks is restricted and should be avoided or limited to the lowest effective dose for the shortest duration possible.
  • Lactation: Indometacin is excreted in breast milk; its use while breastfeeding is generally approached with caution by regulatory bodies.

What should I know about interactions with other medicines?

Hastel (which contains an antihistamine and may contain a decongestant) can interact with a wide range of other medications and substances, potentially leading to increased side effects or reduced effectiveness. It is crucial to inform a healthcare provider of all medicines, supplements, and herbal products currently being taken.

Medications that Increase Sedation

Combining Hastel with other substances that cause drowsiness can significantly enhance the effects of the antihistamine component, increasing the risk of sedation, dizziness, impaired concentration, and slow reaction time. These interactions are of particular concern when driving or operating machinery. Examples of such medications and substances include:

  • Alcohol
  • Opioid pain or cough relievers
  • Sleep aids (e.g., zolpidem)
  • Anxiety medications (e.g., benzodiazepines)
  • Muscle relaxants
  • Certain antidepressants (e.g., tricyclic antidepressants, some SSRIs)

Other Significant Interactions

Interacting Agents Potential Effect
Monoamine Oxidase Inhibitors (MAOIs) Major interaction; may cause severe and potentially fatal reactions, especially if Hastel contains a decongestant. Use must be separated by at least 14 days.
Anticholinergic Drugs Increases the risk of side effects like dry mouth, constipation, and difficulty urinating (e.g., medications for Parkinson's disease, overactive bladder).

Certain fruit juices (like grapefruit, orange, or apple) can interfere with the absorption of some antihistamine components and should be avoided close to the time of taking Hastel. Additionally, taking multiple over-the-counter cold, flu, or allergy products containing the same or similar ingredients as Hastel (e.g., another antihistamine or decongestant) should be avoided to prevent accidental overdose.

Mechanism of Action

How Hastel Works

Hastel's action is defined by its ability to modulate key chemical signaling within the body. Its mechanism focuses strictly on inhibiting a critical enzyme pathway, leading to predictable physiological adjustments.


Molecular Blockade of Prostanoid Synthesis

The primary mechanism of Indometacin involves the non-selective, competitive inhibition of the Cyclooxygenase (COX) enzymes, specifically both COX-1 and COX-2. This targeted enzyme blockade prevents the conversion of Arachidonic Acid into Prostaglandins, primarily Prostaglandin E2 ( PGE2). This suppression of PGE2 synthesis is the foundational molecular step that affects downstream physiological processes, decreasing the concentration of prostanoid mediators in target systems.


Central and Peripheral Pathway Modulation

The drug engages two primary mechanistic domains to shape its physiological consequences. Peripherally, the reduction of PGE2 diminishes its power to sensitize nociceptors (pain receptors) and modulates vascular tone, influencing local capillary permeability. Centrally, Indometacin accesses the hypothalamus, where it resets the core thermoregulatory set-point by suppressing PGE2 levels. These combined actions result in a coordinated reduction in pathway activity within peripheral mechanisms and modulation of the central thermoregulatory set-point.

Dosage and Administration Information

How to Use Levonorgestrel and Ethinyl Estradiol Tablets

This section outlines the instructions for the administration of Levonorgestrel and Ethinyl Estradiol Tablets (referred to as Hastel in this context).

Administration and Dosing Schedule

Route of Administration: Oral.

Dosing Schedule: One tablet is taken daily for 28 consecutive days, without interruption. The regimen consists of 21 consecutive days of one active tablet (containing hormones) followed by 7 consecutive days of one inactive tablet (placebo).

Timing and Preparation: Each tablet must be taken at the same time every day, following the sequence indicated on the blister pack. The first tablet should be taken on an empty stomach. The tablet can be swallowed whole or chewed and then immediately swallowed with a full glass of water.


Procedural Rules

Classification Rule
Starting the Pack Choose either a Day 1 Start (first day of menstrual bleeding) or a Sunday Start (first Sunday after bleeding starts).
Special Conditions If using a Sunday Start, use a nonhormonal contraceptive method for the first seven days.
Missed-Dose Instructions If one active tablet is missed: Take it as soon as possible, even if it means taking two tablets in one day. Continue with the rest of the pack. If two or more active tablets are missed: Consult detailed guidance. Back-up nonhormonal contraception is typically required for seven days.

Connection to the Overall Use Protocol

This protocol mandates a consistent, cyclical administration, ensuring 21 days of active hormone intake followed by a 7-day hormone-free interval. Adherence to the daily timing and the specific procedural steps for missed doses is essential for maintaining the intended effect.

Recent Clinical Evidence

Hastel: Recent Clinical Evidence

Post-Operative Pain Management

Research evidence has explored the use of the drug for moderate-to-severe pain, particularly in post-operative recovery. The primary evidence comes from a key meta-analysis of five Randomized Controlled Trials (RCTs) involving over 1,500 adult participants recovering from major surgery. This analysis reported that patients experienced a difference in recorded pain scores within 24 hours of administration.

Further studies examined whether the drug reduced the need for rescue medication over the following 48 hours. Trial protocols required strict adherence to specific dosing schedules in order to evaluate outcomes.

Chronic Pain Conditions

Regarding chronic conditions, a few cohort studies evaluated the compound in comparison with standard non-opioid treatments, reporting specific measured outcomes. These studies typically involved patients with neuropathic pain who had previously not responded to initial treatments. The available evidence remains limited compared to the data established for acute post-operative use.

Biological Activity and Safety Profile

Studies have examined the proposed biological action of the compound. The compound was observed in relation to outcomes related to pain.

In terms of safety, trial data reported on short-term use in adults. All use of this drug was monitored under medical supervision due to potential side effects in the studies reviewed. Side effects reported included those affecting the central nervous system and the gastrointestinal tract. However, potential gastrointestinal side effects were noted in the studies, and some trials documented co-administered therapies. Long-term use remains an area where evidence is limited, and studies focused on specific durations.

Frequently Asked Questions (FAQ)

Common questions about Hastel (FAQ)


Q: Does Hastel work immediately, or does it take time to notice effects?

Official product information describes that the active component, Indometacin, is absorbed into the bloodstream relatively quickly. The highest concentration of the drug in the blood is typically measured about one to two hours after taking an oral dose. This measure is often used to characterize the time point when the pharmacological activity begins.


Q: What happens if I stop taking Hastel suddenly?

Regulatory guidance indicates that abruptly stopping the medication may be associated with a return of the symptoms the drug was being used to manage. In clinical settings, patients are noted to be monitored during the discontinuation process. Official guidance notes that medical supervision is involved when discontinuing therapy to manage the patient's transition.


Q: What percentage of people in studies experienced the main side effects of Hastel?

Official clinical trial data uses frequency categories to describe the probability of side effects. 'Very Common' effects, such as headache and dizziness, were observed in 1 out of 10 people or more (>10%). Other reactions classified as 'Common,' like nausea and fatigue, were seen in 1 to less than 10 out of every 100 people (1% to <10%).


Q: Can Hastel interact with herbal supplements?

Official documents emphasize the importance of informing a healthcare professional about all medicines and supplements, including herbal products, that are being taken. This is because the drug has properties that suggest a potential for interaction with substances that could affect the central nervous system or have similar pharmacological effects.


Q: Do the side effects of Hastel usually go away after a few days?

Regulatory labeling reports that certain documented side effects, particularly dizziness and nausea, may occur more frequently during the initial four weeks of therapy. This observation suggests that some effects may lessen over time as the body adjusts. However, the official documentation does not specify the exact duration for all adverse reactions.


Q: Are there any foods or drinks that should be avoided while taking Hastel?

Regulatory documents specifically advise caution with certain fruit juices, such as grapefruit, orange, or apple, as they may interfere with the absorption of some components of the medicine. No other common general foods or drinks are specifically listed for avoidance in the official product information.


Q: How long does Hastel typically stay in the body?

The rate at which the active ingredient, Indometacin, is eliminated from the body is defined by its half-life. The half-life is the time it takes for the amount of drug in the body to be reduced by half. For Indometacin, the elimination half-life is reported to be approximately 4.5 hours.


Q: Is Hastel addictive or habit-forming?

Hastel belongs to the Nonsteroidal Anti-inflammatory Drug (NSAID) class. Regulatory authorities have not scheduled the drug as a controlled substance, meaning it is not classified as having a potential for addiction or habit-forming behavior.


Q: Is there a maximum recommended duration for taking Hastel?

Official guidance does not set a single, fixed maximum duration for all patients using this medicine. However, documents warn that the risk of serious adverse events involving the heart or stomach may increase with the length of use. Official labeling documents often describe the use of the lowest effective dose for the shortest duration as the recommended approach.


Q: What does the research say about the long-term use of Hastel?

Regulatory summaries address long-term use by stating that the potential for serious cardiovascular risks and gastrointestinal issues, such as bleeding and perforation, increases the longer the drug is taken. Due to these potential risks, the official labeling supports limiting the duration of use and administering the lowest effective dose.


Q: Does taking Hastel affect laboratory blood tests?

Official safety documents indicate that taking Hastel may affect certain laboratory tests. Monitoring of Liver Function Tests (LFTs) is specifically recommended, particularly during the first six months of treatment, due to potential effects on liver enzyme values.


Q: Does Hastel come in different strengths?

Yes, the official product labeling details that Hastel is prepared in multiple standardized dosage forms. This includes oral capsules, rectal suppositories, and intravenous powder. Each of these different forms is available in various regulated strengths.


Q: Why is Hastel not recommended for everyone with the condition it treats?

Contraindications (reasons the drug must not be used) are established in official labeling to prevent significant adverse outcomes in specific populations. For example, it is not recommended for people who have active peptic ulcers due to the heightened risk of serious gastrointestinal bleeding. Exclusion criteria are determined by the safety profile for each patient group.


Q: Is there a link between Hastel and weight gain or loss?

Adverse event reporting notes potential effects related to fluid retention, or edema. While this is not a direct statement about general weight changes, it indicates a potential effect on the body's fluid balance, as detailed in the official safety profile.


Q: How long after starting Hastel can I expect to see the full effect?

Clinical trials measure outcomes over specific, set periods, such as within 24 hours for acute symptom relief. However, the time required to experience the maximum benefit varies by individual and the condition being addressed. Official regulatory labeling does not specify a single, fixed time to reach the 'full' effect.


Q: Can Hastel be crushed or split?

Official guidance on administration is specific to the dosage form received. Some forms, such as extended-release capsules, are designed to be swallowed whole and may not be split, crushed, or chewed. The precise instruction for modifying the drug form is located within the official patient information leaflet for the specific product.


Q: Does Hastel affect blood pressure?

Regulatory warnings state that NSAIDs, the class of drugs Hastel belongs to, may cause new onset of or worsen existing high blood pressure (hypertension). The official guidance also notes that the medicine may reduce the effectiveness of other medications taken to control blood pressure.

How should Hastel be stored and disposed of?

Storage and Disposal Requirements for Hastel (Indometacin)

Official regulatory documents define specific storage constraints for Indometacin based on its dosage form. Oral capsules and the intravenous (IV) injection powder must be stored at Controlled Room Temperature, 20° to 25°C (68° to 77°F). In contrast, rectal suppositories are typically required to be stored in a refrigerator, 2° to 8°C (36° to 46°F).

All forms must be protected from light and moisture. The IV injection container must be kept in its carton to maintain light protection. Per regulatory requirement, the medication must be stored out of the sight and reach of children.

Expired or unused product must be disposed of in accordance with local pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Hastel found in:

A-Z Index: